Wang S W, Cheng T T
Section of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.
Lupus. 2005;14(6):483-5. doi: 10.1191/0961203305lu2090cr.
A 51 year old woman with systemic lupus erythematosus (SLE) serially developed thrombocytopenia, arthritis, lupus nephritis, pleuritis, mesenteric vasculitis and refractory hemolytic anemia during the past 19 years prior to presentation. The woman had been managed with high doses of prednisolone, splenectomy, methylprednisolone pulse therapy and cytotoxic drugs, including oral cyclophosphamide, azathioprine, mexotrexate and monthly parenteral cyclophosphamide for hemolytic anemia. After two months of therapeutic trial with Cyclosporin A (CsA) (3 mg/kg), the follow-up hemoglobin (Hb) level was increased to 12.0 gm% and the dose ofprednislone was reduced to 5 mg every other day without occurring rebound during the subsequent three months. There were no obvious side effects from the medication.
一名51岁的系统性红斑狼疮（SLE）女性患者，在就诊前的19年中陆续出现血小板减少、关节炎、狼疮性肾炎、胸膜炎、肠系膜血管炎和难治性溶血性贫血。该女性患者曾接受大剂量泼尼松龙、脾切除术、甲泼尼龙冲击疗法以及细胞毒性药物治疗，包括口服环磷酰胺、硫唑嘌呤、甲氨蝶呤以及针对溶血性贫血的每月一次静脉注射环磷酰胺。在使用环孢素A（CsA）（3毫克/千克）进行两个月的治疗试验后，随访血红蛋白（Hb）水平升至12.0克%，泼尼松龙剂量减至隔日5毫克，在随后的三个月中未出现反弹。用药期间没有明显的副作用。
